Palisade Bio Inc PALI Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.12 down $0.02, 1.75% at close Nov 13
Last close · Previous close $1.14
- Market cap
- At the Nov 13 close
- P/E ratio
- 1.23On last 12 months’ EPS
- Diluted EPS
- $0.91Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.12down $0.02, 1.75%Fri, Nov 13 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.14Nov 12
- Volume1.46MNov 13 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.75MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.08 to $2.86; now $1.12
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 13 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PALI trailed the S&P 500 in all 7 periods.
| Period | PALI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PALI: down 23.5% S&P 500: down 3.0% | PALI trailed the S&P 500 by 20.5 percentage points Trailed |
| 3M | PALI: down 47.9% S&P 500: down 2.8% | PALI trailed the S&P 500 by 45.1 percentage points Trailed |
| YTD | PALI: down 52.3% S&P 500: up 11.5% | PALI trailed the S&P 500 by 63.8 percentage points Trailed |
| 1Y | PALI: down 40.1% S&P 500: up 13.5% | PALI trailed the S&P 500 by 53.6 percentage points Trailed |
| Long term | ||
| 3Y | PALI: down 85.8% S&P 500: up 77.7% −47.9% vs +21.1% a year | PALI trailed the S&P 500 by 163.5 percentage points Trailed |
| 5Y | PALI: down 99.9% S&P 500: up 72.6% −77.6% vs +11.5% a year | PALI trailed the S&P 500 by 172.5 percentage points Trailed |
| 10Y | PALI: down 100.0% S&P 500: up 308.4% −71.6% vs +15.1% a year | PALI trailed the S&P 500 by 408.4 percentage points Trailed |
$10,000 invested in PALI 10 years ago (Nov 11, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $40,844.
PALI trailed the S&P 500 in all 7 periods.
| Period | PALI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PALI: down 23.5% S&P 500: down 3.0% | PALI trailed the S&P 500 by 20.5 percentage points Trailed |
| 3M | PALI: down 47.9% S&P 500: down 3.0% | PALI trailed the S&P 500 by 44.9 percentage points Trailed |
| YTD | PALI: down 52.3% S&P 500: up 10.6% | PALI trailed the S&P 500 by 62.9 percentage points Trailed |
| 1Y | PALI: down 40.1% S&P 500: up 12.3% | PALI trailed the S&P 500 by 52.4 percentage points Trailed |
| Long term | ||
| 3Y | PALI: down 85.8% S&P 500: up 71.4% −47.9% vs +19.7% a year | PALI trailed the S&P 500 by 157.2 percentage points Trailed |
| 5Y | PALI: down 99.9% S&P 500: up 61.4% −77.6% vs +10.1% a year | PALI trailed the S&P 500 by 161.3 percentage points Trailed |
| 10Y | PALI: down 100.0% S&P 500: up 248.6% −71.6% vs +13.3% a year | PALI trailed the S&P 500 by 348.6 percentage points Trailed |
$10,000 invested in PALI 10 years ago (Nov 11, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $34,857.
All-time high
$5,452,200.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Dec 20, 2006.
Stock splits
5
Latest: 1-for-15 on . Share counts adjust after each split.
All 5 splits
- 1-for-15
- 1-for-50
- 1-for-6
- 1-for-20
- 1-for-13
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $500.00K
- Net income
- −$43.70M
- Diluted EPS
- $0.91
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$3.34M | −$0.69 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$2.23M | −$0.47 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$2.78M | −$0.58 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$2.87M | −$0.38 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$8.90M | $1.08 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$9.60M | −$0.05 |
| Q2 FY26 (Jun 30, 2026) | $500.00K | −$10.57M | −$0.05 |
| Q3 FY26 (Sep 30, 2026) | $0.00 | −$14.62M | −$0.07 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$26.62M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$14.55M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $250.00K | −$12.32M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$14.44M | −$10.19 |
| FY25 (Dec 31, 2025) | $0.00 | −$16.78M | −$0.30 |
Margins
- Gross 100.0%
- Operating −9,625.4%
- Net −8,739.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$26.40MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$26.40MLast 12 months
- Capital spending$0.00Last 12 months
- −5,279.2%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $135.07MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $113.67MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$0.00As of Sep 30, 2026
- Net cash$113.67MAs of Sep 30, 2026
- 20.16As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −35.6%Last 12 months
Over the last 12 months, Palisade Bio lost money: its net loss was 35.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −34.0%Last 12 months
Over the last 12 months, Palisade Bio’s net loss was 34.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Palisade Bio Inc
Palisade Bio is a late-stage biopharmaceutical company advancing oral therapies that aid patients suffering with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s lead clinical asset LB1148 is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from completed Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Maryland, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PALI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PALI stock FAQ
What is PALI stock’s price today?
Palisade Bio (PALI) traded at $1.12 at the close on , down $0.02 (1.75%) from the previous close of $1.14. Over the past 52 weeks it has traded between $1.08 and $2.86.
If you invested $1,000 in PALI 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PALI on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $1 if invested five years ago and $599 if invested one year ago. Past performance doesn’t predict future returns.
What is PALI’s P/E ratio?
PALI trades at 1.2 times its diluted earnings over the four quarters to ($0.91 per share), at the close. (How the P/E ratio works.)
How much revenue does Palisade Bio make?
Palisade Bio reported $500.0 thousand of revenue over the four quarters to . In its latest quarter (Q3 FY26, ended ) revenue was $0.0 thousand.
Is Palisade Bio profitable?
Not over the four quarters to . Palisade Bio reported a net loss of $43.7 million across those four quarters on $500.0 thousand of revenue.
What are PALI’s earnings per share?
PALI’s diluted earnings per share were $0.91 over the four quarters to , compared with −$2.12 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.07 per share, against −$0.38 a year earlier (how EPS works).
Does PALI pay a dividend?
Palisade Bio hasn’t paid a dividend in the last twelve months.
What is PALI’s 52-week high and low?
Over the past 52 weeks PALI has traded as low as $1.08 and as high as $2.86. At $1.12 at the close on , it is 60.8% below that high and 3.7% above the low.
What is PALI’s all-time high?
PALI’s highest closing price was $5,452,200.00 on , adjusted for stock splits. At $1.12 at the close on , it is 100.0% below that record.
Has PALI stock ever split?
Yes, five times: 1-for-13 on ; 1-for-20 on ; 1-for-6 on ; 1-for-50 on ; 1-for-15 on .
How has PALI stock performed?
Including dividends and measured to the close on , PALI has returned −52.3% so far this year and −40.1% over the past year, and −99.9% over five years (−77.6% a year). Over the same periods the S&P 500, measured by SPY, returned +11.5%, +13.5% and +72.6%. Past performance doesn’t predict future returns.
What sector and industry is Palisade Bio in?
Palisade Bio is in the Healthcare sector and the Biotechnology industry, and is headquartered in Maryland, USA.
What exchange does PALI trade on?
Palisade Bio trades on the Nasdaq under the ticker symbol PALI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.









